Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Breathes Sigh Of Relief Over UK Batch Release Move

Executive Summary

One of the key regulatory conundrums thrown up by Brexit has been addressed after the government decided to continue using a list of approved countries to waive drug import testing requirements.

You may also be interested in...



Batch Testing ‘Could Double’ Under Govt Proposals For Great Britain

The UK government is consulting on a set of options for batch testing of imported medicines as it seeks to balance patient safety principles with the need to avoid overly burdensome import requirements.

EU Fees Revision A ‘Once-In-A-Generation’ Chance To Solve Resource Challenges

COVID-19 and Brexit have put a great strain on the resources of the EU medicines regulatory system, but the planned review of the EU fee system could produce a system that is more flexible, efficient and better able to respond rapidly to emerging technologies and the needs of health care systems, says EFPIA.

New French Body To Lead Efforts Against Drug Shortages

A new committee including representatives of the French pharma industry, health professionals and patients is to lay the groundwork for a longer-term approach to preventing and managing medicine supply chain issues. A separate initiative launched by the prime minister will look at medicines access issues and strengthening the French manufacturing base.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel